Relay Therapeutics CFO sells 1,469 shares

The sale covered tax withholding obligations tied to 3,269 RSUs that vested October 27, 2026, and was made without the CFO's discretion.

Rhea-AI Filing Summary

Relay Therapeutics, Inc. (RLAY) Chief Financial Officer Thomas Catinazzo sold 1,469 shares of common stock on October 28, 2026, at $18.62 per share. The sale covered income tax withholding obligations upon the vesting of 3,269 restricted stock units on October 27; Catinazzo had no discretion over the sale, which was transacted in accordance with the issuer’s policies regarding RSU vesting. He directly held 103,665 shares after the transaction, including 3,269 shares underlying RSUs. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Net Seller: 1,469 shares

Net Sell 1 txn

Insider Catinazzo Thomas

Role Chief Financial Officer

Sold 1,469 shs ($27K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	1,469	$18.62	$27K

Holdings After Transaction: Common Stock — 103,665 shares (Direct)

Footnotes (2)

1. F1. Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 3,269 shares of restricted stock units ("RSUs") on October 27, 2026. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
2. F2. Includes 3,269 shares underlying RSUs.

Key Figures

Common shares sold: 1,469 shares Sale price per share: $18.62 per share Restricted stock units vested: 3,269 shares +1 more

4 metrics

Common shares sold 1,469 shares October 28, 2026

Sale price per share $18.62 per share Sale on October 28, 2026

Restricted stock units vested 3,269 shares October 27, 2026

Shares held after transaction 103,665 shares Includes 3,269 shares underlying RSUs

Key Terms

restricted stock units (RSUs), vesting, income tax withholding obligations

3 terms

restricted stock units (RSUs) financial

"vesting of 3,269 shares of restricted stock units (RSUs)"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

vesting financial

"upon the vesting of 3,269 shares"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

income tax withholding obligations financial

"to cover the reporting person's income tax withholding obligations"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RLAY shares did Thomas Catinazzo sell, and at what price?

Thomas Catinazzo sold 1,469 shares on October 28, 2026, at $18.62 per share to cover income tax withholding obligations upon vesting of 3,269 RSUs on October 27. He had no discretion over the sale; it was transacted in accordance with Relay Therapeutics’ policies regarding RSU vesting. No Rule 10b5-1 plan is reported for the sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/30/2026 - 04:15 PM EDT Accepted by SEC EDGAR 10/30/2026 - 04:14 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Catinazzo Thomas

(Last) (First) (Middle)

C/O RELAY THERAPEUTICS, INC.

60 HAMPSHIRE STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Relay Therapeutics, Inc. [ RLAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/28/2026		S		1,469(1)	D	$18.62	103,665(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 3,269 shares of restricted stock units ("RSUs") on October 27, 2026. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.

2. Includes 3,269 shares underlying RSUs.

	/s/ Soo-Yeun Lim, as Attorney-in-Fact	10/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)